Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:20 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Variable dose Clear all
Recruiting Phase 1 Interventional

CD4CAR for CD4+ Leukemia and Lymphoma

NCT03829540
View directory record Official record
Conditions
T-cell Lymphoma, T-cell Leukemia
Interventions
CD4CAR
Biological
Lead sponsor
Huda Salman
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2042
U.S. locations
6
States / cities
Miami, Florida • Indianapolis, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Canakinumab (investigational), Placebo, Methotrexate (MTX)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Nov 1, 2026, 9:20 AM EST
Terminated Phase 2 Interventional Results available

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

NCT01173679
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
dasatinib, Rituximab, fludarabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 3 Interventional Results available

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

NCT04093024
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 3 Interventional Results available

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

NCT01884311
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinaemia, Hyperimmunoglobulin M Syndrome
Interventions
Subgam
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Chandler, Arizona • Irvine, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Nov 1, 2026, 9:20 AM EST
Completed No phase listed Observational

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

NCT00268528
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission
Interventions
Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Questionnaire Administration, Study of Socioeconomic and Demographic Variables
Behavioral · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
124
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 105 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Nov 1, 2026, 9:20 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

(VIII): The Eight Study and Immunologic Response Sub-study

NCT05237024
View directory record Official record
Conditions
Vaccine Reaction
Interventions
Not listed
Lead sponsor
physIQ, Inc.
Industry
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 4 Interventional

Methylprednisolone Taper After Total Knee Replacement

NCT05859269
View directory record Official record
Conditions
Knee Arthritis
Interventions
Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 1, 2026, 9:20 AM EST
Active, not recruiting Phase 4 Interventional

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Aflibercept 8mg
Drug
Lead sponsor
Edward Wood, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Austin, Texas • Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 1, 2026, 9:20 AM EST
Suspended Phase 1 Interventional

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

NCT06071624
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia
Interventions
CD4CAR
Biological
Lead sponsor
Huda Salman
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2043
U.S. locations
4
States / cities
Miami, Florida • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 1, 2026, 9:20 AM EST
Recruiting Not applicable Interventional

Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy

NCT06686680
View directory record Official record
Conditions
Knee Osteoarthristis, ACL Injuries, Post-Traumatic
Interventions
extracorporeal shockwave therapy (ESWT), Sham Comparator
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 9:20 AM EST
Terminated Phase 4 Interventional Results available

Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

NCT02946580
View directory record Official record
Conditions
Constipation
Interventions
MOVANTIK™ (naloxegol), Sugar Pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease
Interventions
Epoetin Hospira, Epogen Amgen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Azusa, California • Bakersfield, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

NCT00728780
View directory record Official record
Conditions
Adverse Events, Pharmacokinetic Variables
Interventions
ABT-143, ABT-335 and rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

NCT02053935
View directory record Official record
Conditions
Hyperglycemia, Sepsis
Interventions
Dopamine
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Nov 1, 2026, 9:20 AM EST
Recruiting Phase 1 Interventional

MOv19-BBz CAR T Cells in FRa+ Cancers

NCT07116057
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
Interventions
MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing
Biological · Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 1, 2026, 9:20 AM EST
Terminated Phase 2 Interventional Results available

Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

NCT05034874
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
IXT-m200, Placebo
Drug · Other
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Nov 1, 2026, 9:20 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Effects of Nicotine on Brain Activity as Measured by fMRI

NCT01037153
View directory record Official record
Conditions
Nicotine Dependence, Drug Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 4 Interventional Results available

Adult Patients Undergoing Open Colectomy MA402S23B303

NCT01507246
View directory record Official record
Conditions
Bowel Obstruction
Interventions
IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Riverdale, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 1Phase 2 Interventional

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NCT04720976
View directory record Official record
Conditions
Solid Tumor, NSCLC
Interventions
JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib
Drug
Lead sponsor
Allist Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Nov 1, 2026, 9:20 AM EST
Completed Not applicable Interventional

Daily Vitamin K in Patients on Warfarin With Unstable INRs

NCT00287313
View directory record Official record
Conditions
Anticoagulants, Warfarin
Interventions
Vitamin K
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 2 Interventional

Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)

NCT01220713
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post-Concussive Syndrome
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
19 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Portsmouth, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Nov 1, 2026, 9:20 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

NCT02199496
View directory record Official record
Conditions
Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
Interventions
Stelara (ustekinumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Nov 1, 2026, 9:20 AM EST